Uveal melanoma

Cancer Treatment Reviews

Volumn 38, Issue 5, 2012, Pages 549-553

  Spagnolo, Francesco ^a   Caltabiano, Graziano ^a   Queirolo, Paola ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Enucleation; Ipilimumab; Proton beam irradiation; Targeted therapies; Uveal melanoma

Indexed keywords

ALPHA2A INTERFERON; BEVACIZUMAB; FOTEMUSTINE; IPILIMUMAB; SELUMETINIB; SUNITINIB; TEMOZOLOMIDE; VINCRISTINE SULFATE;

ARTIFICIAL EMBOLISM; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CUTANEOUS MELANOMA; DRUG EFFICACY; DRUG SAFETY; GENETIC ANALYSIS; HIGH RISK POPULATION; HUMAN; LIVER METASTASIS; OVERALL SURVIVAL; PHOTON THERAPY; PROGNOSIS; REVIEW; UVEA MELANOMA;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; MELANOMA; PIPERAZINES; PYRIMIDINES; UVEAL NEOPLASMS;

EID: 84861189084     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.01.002     Document Type: Review

References (50)

1. Hu D.N., Yu G.P., Bedikian A.Y. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin 2006, 46(1):151-166.
2. Damato B. Treatment of primary intraocular melanoma. Expert Rev Anticancer Ther 2006, 6:493-506.
3. Stalicky S.E., Holt P.E., Giblin M., Taylor S., Conway M. Australian cancer network clinical practice guidelines for the management of ocular and periocular melanoma: an evidence-based literature analysis. Clin Exp Ophthalmol 2008, 36:646-658.
4. Frenkel S., Hendler K., Pe'er J. Uveal melanoma in Israel in the last two decades. Characterization, treatment and prognosis. Isr Med Assoc J 2009, 11:280-285.
5. Kujala E., Makitie T., Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003, 44(11):4651-4659.
6. Diener-West M., Reynolds S.M., Agugliaro D.J., et al. Development of metastatic disease after enrollment in the COMS trial for treatment of choroidal melanoma: collaborative ocular melanoma study group report No. 26. Arch Ophthalmol 2005, 123:1639-1643.
7. Gragoudas E.S., Egan K.M., Seddon J.M., et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991, 98:383-390.
8. Singh A.D., Borden E.C. Metastatic uveal melanoma. Ophthalmol Clin North Am 2005, 18:143-150.
9. Bedikian A.Y. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin 2006, 46:151-166.
10. Singh A.D., Shields C.L., Shields J.A. Prognostic factors in uveal melanoma. Melanoma Res 2001, 11:255-263.
11. Zuidervaart W., Van Nieurpoort F., Stark M., et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer 2005, 92:2032-2038.
12. Landreville S., Agapova O.A., Harbour J.W. Emerging insights into the molecular genesis of uveal melanoma. Future Oncol 2008, 4:629-636.
13. Hofmann U.B., Kauczok-Vetter C., Houben R., Becker U.C. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res 2009, 15(1):324-329.
14. Van Raamsdonk C.D., Griewank K.G., Crosby M.B., Garrido M.C., et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010, 23:2191-2199.
15. Lamba S., Felicioni L., Buttitta F., et al. Mutational profile of GNAQQ209 in human tumors. PLoS One 2009, 4:e6833.
16. Besaratinia A., Pfeifer G.P. Uveal melanoma and GNA11 mutations: a new piece added to the puzzle. Pigment Cell Melanoma Res. 2011, 24(1):18-20.
17. Prescher G., Bornfeld N., Hirche H., Horsthemke B., Jockel K.H., Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996, 347:1222-1225.
18. White V.A., Chambers J.D., Courtright P.D., Chang W.Y., Horsman D.E. Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer 1998, 83:354-359.
19. Damato B., Coupland S.E. Translating uveal melanoma cytogenetics into clinical care. Arch Ophthalmol 2009, 127(4):423-429.
20. Damato B., Dopierala J., Klaasen A., van Djik M.C., Sibbring J.S., Coupland S.E. Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. Invest Ophthalmol Vis Sci 2009, 50(7):3048-3055.
21. Li W., Gragoudas E.S., Egan K.M. Metastatic melanoma death rates by anatomic site after proton beam irradiation for uveal melanoma. Arch Ophthalmol 2000, 118:1066-1070.
22. Onken M.D., Worley L.A., Ehlers J.P., Harbour J.W. Gene expression profiling in uveal melanoma reveals two molecular classes, predicts metastatic death. Cancer Res 2004, 64:7205-7209.
23. Damato B., Coupland S., Robertson D.M., Shields J.A., Shields C.L., Takami S., et al. Genomic Typing of uveal melanoma (Comments and opinion). Arch Ophthalmol 2009, 127(1):113-115.
24. Shields C.L., Ganguly A., Bianciotto C., Turaka K., Shields J.A. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology 2011, 118(2):396-401.
25. Damato B. Does ocular treatment of uveal melanoma influence survival?. Br J Cancer 2010, 103:285-290.
26. The Collaborative ocular Melanoma Study (COMS) randomized trial of iodine 125 brachitherapy for choroidal melanoma, III: initial mortality findings. COMS report No. 18. Arch Ophthalmol 2001;119:969-982.
27. Desjardins L., Dorval T., Lévy C., Cojean I., Schlienger P., Salmon R.J., et al. Randomized study on adjuvant therapy by DTIC in choroidal melanoma. Ophthalmologie 1998, 12:168-173.
28. Voelter V., Schalenbourg A., Pampallona S., Peters S., Halkic N., Denys A., et al. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients. Melanoma Res 2008, 18(3):220-224.
29. Lane A.M., Egan K.M., Harmon D., Holbrook A., Munzenrider J.E., Gragoudas E.S. Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. Ophthalmology 2009, 116(11):2206-2212.
30. Hsueh E.C., Essner R., Foshag L.J., Ye X., Wang H.J., Morton D.L. Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer 2004, 100:122-129.
31. Sato T. Locoregional management of hepatic metastases from primary uveal melanoma. Semin Oncol 2010, 37(2):127-138.
32. Becker J.C., Terheyden P., Kampgen E., et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 2002, 87:840-845.
33. Peters S., Voelter V., Zografos L. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 2006, 17:578-583.
34. Sato T., Eschelman D.J., Gonsalves C.F., et al. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony stimulating factor. J Clin Oncol 2008, 26:5436-5442.
35. Alexander H.R., Libutti S.K., Pingpank J.F., et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to the liver. Clin Cancer Res 2003.
36. Queirolo P., Acquati M. Medical treatment of uveal melanoma. Tumori 2007, 93(Suppl. 3):27-30.
37. Pyrhonen S., Hahka-kemppinen M., Muhonen T. Chemioimmunotherapy with bleomicin, vincristine, lomustine, dacarbazine (BOLD) and human leukocyte interferon for metastatic uveal melanoma patients. Cancer 2002, 95:2366-2372.
38. Kivela T., Suciu S., Hansson J. Bleomicin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer 2003, 39:1115-1120.
39. Bedikian A.Y., Papadopoulos N., Plager C., Eton O., Ring S. Phase II evaluation of temozolomide in metastatic choroidal melanoma. Melanoma Res 2003, 13(3):303-306.
40. Schmittel A., Schuster R., Bechrakis N.E., Siehl J.M., Foerster M.H., Thiel E., et al. A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma. Melanoma Res 2005, 15(5):447-451.
41. Schmittel A., Scheulen M.E., Bechrakis N.E. Phase II trial of cisplatin, gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol 2006, 17:578-583.
42. O'neill P.A., Butt M., Eswar C.V., Gillis P., Marshall E. A prospective single arm phase II study of dacarbazine and treosulfan as first line therapy in metastatic uveal melanoma. Melanoma Res 2006, 16:245-248.
43. Homsi J., Bedikian A.Y., Papadopoulos N.E., Kim K.B., Hwu W.J., Mahoney S.L., et al. Phase II open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. Melanoma Res 2010, 20(6):507-510.
44. Bedikian A.Y., Papadopoulos N.E., Kim K.B., Vardeleon A., Smith T., Lu B., et al. A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma. Melanoma Res 2008, 18:400-404.
45. Queirolo P., Acquati M. Targeted therapies in melanoma. Cancer Treat Rev 2006, 32:524-531.
46. Gray-Schopfer V., Wellbrock C., Marais R. Melanoma biology and new targeted therapy. Nature 2007, 445:851-857.
47. Gunther J.B., Altaweel M.M. Bevacizumab (avastin) for the treatment of ocular disease. Surv Ophthalmol 2009, 54(3):372-400.
48. Chan K.R., Gundala S., Laudadio M. A pilot study using sunitinib malate as therapy in patients with stage IV uveal melanoma. J Clin Oncol 2008, 26(Suppl.). Abstract 9047.
49. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723.
50. Danielli R, Queirolo P, Testori A, Plummer R, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Presented at the Joint ECCO 15-34th ESMO congress 2009.